Navigation Links
Instrumentation Laboratory Receives 510(k) Clearance From FDA for HemosIL(R) Liquid Heparin Assay
Date:6/15/2009

- Ready-to-use, Chromogenic Assay for Monitoring UF and LMW Heparin -

BEDFORD, Mass., June 15 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its HemosIL Liquid Heparin assay. Previously, the Company received a license for the product from Health Canada, as well as a European CE IVD Mark. With this latest clearance in the US, the company can now initiate commercialization in North America and European countries. IL will coordinate commercialization of the product in North America, with their distribution partner, Beckman Coulter, Inc.

HemosIL Liquid Heparin is a liquid, ready-to-use, universal heparin assay for the quantitative determination of unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) activity in human citrated plasma. Fully automated on IL Hemostasis Testing Systems, it is a one-stage chromogenic assay, with excellent correlation with traditional two-stage assays, providing greater simplicity and efficiency. This allows customers to move testing from the specialty lab to the routine lab, ensuring availability 24 hours/day, 7 days/week.

"We are very pleased with the rapid clearance of HemosIL Liquid Heparin by the FDA. This speaks to its significance to the medical community," said Giovanni Russi, Director of Marketing, Hemostasis Reagents at Instrumentation Laboratory. "It is an exciting breakthrough for healthcare providers who treat the thousands of patients around the world using UFH and LMWH. This will enable more rapid and accurate monitoring of prophylaxis and treatment."

Instrumentation Laboratory Receives 510(K) Clearance From FDA for HemosIL Liquid Heparin Assay

UFH and LMWH are widely used anticoagulants, administered for the prophylaxis and treatment of a number of cardiovascular disorders, including venous thromboembolism, unstable angina and acute myocardial infarction. They are also administered to patients who undergo orthopedic, cardiovascular and other surgeries. UFH and LMWH monitoring is critical in assessing and determining the appropriate anticoagulant activity in these patients. Due to the extensive number of such patients, the availability of a chromogenic anti-Xa assay, readily and always available is key in ensuring effective monitoring, 24 hours a day/7 day a week.

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include critical care systems, hemostasis systems and information management systems. IL's GEM(R) product offerings, part of the critical care line, include the GEM Premier(TM) 4000 analyzer with Intelligent Quality Management (iQM(R)), the new GEM Premier 3500 analyzer with iQM and the GEM PCL Plus, a portable coagulation analyzer. IL's hemostasis portfolio includes the ACL TOP(R) Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP and the new ACL TOP 500 CTS. IL also offers the new ACL AcuStar Hemostasis Testing System, the ACL ELITE(R) and ELITE PRO, other hemostasis analyzers and the HemosIL(R) line of reagents. IL is based in Bedford, Massachusetts.

The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL, ACL TOP, ACL ELITE, ACL AcuStar, Premier and GEM OPL are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.


'/>"/>
SOURCE Instrumentation Laboratory
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Instrumentation Laboratory Launches ACL AcuStar(TM) Hemostasis Testing System
2. Instrumentation Laboratory Wins Patent Infringement and Unfair Competition Trial Against Diagnostica Stago Relating to Reagents for Hemostasis Diagnostics
3. Instrumentation Laboratory Wins Extended Agreement With MedAssets Supply Chain Systems for Critical Care Portfolio
4. Instrumentation Laboratory Announces ILeader Panel of Experts as Part of 50th Anniversary Program
5. Frost & Sullivan Recognizes Waters Corporation for Its Pioneering, High Customer Value Analytical Instrumentation Product, SYNAPT HDMS
6. Instrumentation Laboratory Receives Performance Award from Premier for Second Consecutive Year
7. Instrumentation Laboratory Launches ACL Top(R) 500 CTS Hemostasis Testing System
8. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
9. Instrumentation Laboratory Named Top of Class by Respiratory Care Managers
10. Legislation Will Expand Access to Life-Saving Laboratory Tests
11. Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: